Novartis Completes Tender Offer for Regulus Therapeutics

Novartis has concluded its tender offer to acquire Regulus Therapeutics, with approximately 74.49% of outstanding shares validly tendered and not withdrawn by the expiration deadline on June 24, 2025. The acquisition, executed through Novartis' subsidiary Redwood Merger Sub Inc., offered $7.00 in cash per share plus a contingent value right (CVR) of an additional $7.00 upon achieving a specified regulatory milestone. 

The transaction is set to close promptly following the acceptance of the tendered shares. This move aligns with Novartis' strategic focus on expanding its renal disease portfolio, particularly through Regulus' lead asset, farabursen—a next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). 

The acquisition underscores Novartis' commitment to advancing innovative therapies in areas of high unmet medical need.